Onco Actu du 4 novembre 2015

	3.1 Tabac
Trial to study smoking-cessation therapy tailored to a smoker’s DNA [Washington University in St. Louis] Ultimately, the researchers want to learn how a smoker’s genetic makeup influences how much one smokes and how he or she will respond to drugs designed to help smokers quit. The team’s earlier research indicates that DNA variations can influence the effectiveness of various smoking-cessation medications.​​​​​​​​​​​​​​​​​
	4. Dépistage, diagnostic et pronostic
Study: Only 1 in 5 US pancreatic cancer patients get this key blood test at diagnosis [Mayo Clinic] Researchers analyzed outcomes for 97,000 patients. The tumor marker whose impact they studied is known as CA 19-9. It is associated with several cancers, including pancreatic cancer, and can be measured in the blood of most people: 10 percent do not produce it. Pancreatic cancer patients who didn’t secrete CA 19-9 were also studied.
Public don't realise screening can help prevent cancer [NRCI] Professor Charles Swanton, chair of the 2015 NCRI Cancer Conference, said: “These results show that we need to get better at helping people to understand what cancer screening is for."
	4.5 Dép., diag. & prono. - Colorectal
Naturally high oestrogen levels may lowen women's bowel cancer risk after menopause [NCRI] “By tracking older women’s hormone levels we could find those at higher and lower risk of bowel cancer, and we may one day be able to tailor the amount of screening women are offered based on this information.”
	4.9 Dép., diag. & prono. - Sein
Breast Cancer - Pipeline Review, 2015 [Report Buyer] GlobalData's Medical Devices sector report, “Breast Cancer - Pipeline Review, 2015" provides an overview of Breast Cancer diagnostic tests currently in pipeline stage.
	5. Traitements
Prostate cancer treatment time 'could be halved' with more intense radiotherapy [The Telegraph] "Overall our results make a compelling case to change practice within the NHS and move from a 37-day regime to one that lasts 20 days. As well as saving men from repeated hospital visits, this could save tens of millions of pounds per year."
	5.2 Pharma
Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound [Boehringer Ingelheim] First patients enrolled in pivotal Phase II global trial evaluating BI 1482694 (HM61713) in patients with T790M mutation-positive NSCLC.
GSK aims to file up to 20 new drugs for approval by 2020 [Reuters] Despite having sold its marketed cancer drugs to Novartis, GSK is still investing in oncology and it announced a deal with Merck to test its experimental OX40 cancer drug alongside the U.S. company's Keytruda in solid tumors.
	5.2.1 Pharma - Partenariats
Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners [FierceBiotech] For Sanofi, the partnership comes amid a cautious re-embrace of cancer R&D.
Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program [BMS] The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment [Merck] Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
	6. Lutte contre les cancers
NCRI cancer conference day 2: big data, immunotherapy and prizes [Cancer Research UK] Monday morning’s papers had lots of coverage of research presented at yesterday’s conference: data on the unacceptably high death rates of patients diagnosed as an emergency made several papers. But there was still more fascinating research presented at the conference as it got into gear for day two.
	6.11 Patients
Rerouted, not derailed: resuming a young life after cancer [Cancer World] Paediatric oncologists are highly focused on how to minimise and manage the life-long damage their treatments inflict on young patients’ health. But for young survivors, the most immediate challenge is how to get an interrupted life back on track.